Diffusion Pharmaceuticals, Inc. to Present at the H.C. Wainwright Global Life Sciences Conference
05 March 2021 - 8:05AM
Diffusion Pharmaceuticals Inc. (NASDAQ:
DFFN) (“Diffusion” or the “Company”), an innovative
biopharmaceutical company developing novel therapies that enhance
the body’s ability to deliver oxygen to areas where it is needed
most, announced today that Robert J. Cobuzzi, Ph.D., CEO of
Diffusion, will present at the H.C. Wainwright Global
Life Sciences Conference taking place March 9-10, 2021. The
presentation will be available on demand during the virtual event
for all registered attendees.
Event details are as follows:
Event: |
H.C. Wainwright Global Life Sciences
Conference |
Date: |
Tuesday, March 9, 2021 to Wednesday, March 10, 2021 |
Time:Registration: |
Available on
Demand https://hcwevents.com/globalconference/ |
During the presentation, Dr. Cobuzzi
will provide an overview of Diffusion’s recent corporate
achievements, planned clinical trials, as well as potential
milestones. Our presentation will be available here, on the
Investor Relations section of our website following the
conference.
About Diffusion Pharmaceuticals Inc.
Diffusion Pharmaceuticals Inc. is an innovative
biopharmaceutical company developing novel therapies that enhance
the body’s ability to deliver oxygen to areas where it is needed
most. Diffusion’s lead product candidate, trans sodium
crocetinate (TSC), is being developed to enhance the diffusion
of oxygen to tissues with low oxygen levels, also known as hypoxia,
a serious complication of many of medicine’s most intractable and
difficult-to-treat conditions. In addition to TSC, Diffusion’s
product candidate DFN-529, a novel, allosteric PI3K/Akt/mTOR
Pathway inhibitor, is in early-stage development. For more
information, please visit us at www.diffusionpharma.com.
Forward-Looking Statements
This press release includes express and implied
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, as amended, including
regarding the anticipated use of proceeds from the offering. The
Company may, in some cases, use terms such as “believes,”
“estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,”
“could,” “might,” “will,” “should,” “approximately,” or other words
that convey uncertainty of future events or outcomes to identify
these forward-looking statements. Although the Company believes
that it has a reasonable basis for each forward-looking statement
contained herein, forward-looking statements by their nature
involve risks and uncertainties, known and unknown, many of which
are beyond the Company’s control, and as a result the Company’s
actual results could differ materially from those expressed or
implied in any forward-looking statement. Particular risk and
uncertainties include, among other things, those related to: the
Company’s ability to design, initiate, execute, and complete its
ongoing and planned studies evaluating TSC;; the Company’s ability
to develop and commercialize TSC or any other product candidate;
general economic, political, business, industry, and market
conditions, including the ongoing COVID-19 pandemic; and the other
factors discussed under the heading “Risk Factors” in the Company’s
filings with the U.S. Securities and Exchange Commission (“SEC”).
Any forward-looking statements in this press release speak only as
of the date hereof (or such earlier date as may be identified) and,
except as required by applicable law, rule, or regulation, the
Company undertakes no obligation to update any such statements
after the date hereof.
ContactsInvestors:Tiberend
Strategic Advisors, Inc. Maureen McEnroe, CFA/Miriam Weber
Miller (212) 375-2664 / (212)
375-2694mmcenroe@tiberend.com / mmiller@tiberend.com
Media:Jeffrey FreedmanRooneyPartners(646)
432-0191 jfreedman@rooneyco.com
Diffusion Pharmaceuticals (NASDAQ:DFFN)
Historical Stock Chart
From Apr 2024 to May 2024
Diffusion Pharmaceuticals (NASDAQ:DFFN)
Historical Stock Chart
From May 2023 to May 2024